In addition, we recently reported that in patients with high PD‐L1 expression who received pembrolizumab monotherapy as a first‐line treatment for NSCLC, GPS was significantly correlated with both PFS and OS and BMI was significantly correlated with OS, which could be used to predict outcomes in these patients.9 This evidence concerns the gene CD274 and non-small cell lung carcinoma.